Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.05 Insider Own0.70% Shs Outstand144.51M Perf Week-4.38%
Market Cap6.21B Forward P/E62.10 EPS next Y0.69 Insider Trans6.19% Shs Float143.60M Perf Month-16.60%
Income-6.70M PEG- EPS next Q0.14 Inst Own96.10% Short Float3.36% Perf Quarter-9.46%
Sales563.10M P/S11.03 EPS this Y-33.30% Inst Trans-0.04% Short Ratio6.49 Perf Half Y-11.73%
Book/sh9.34 P/B4.60 EPS next Y41.22% ROA-0.40% Target Price50.92 Perf Year27.58%
Cash/sh3.82 P/C11.25 EPS next 5Y13.10% ROE-0.60% 52W Range29.36 - 54.25 Perf YTD5.68%
Dividend- P/FCF- EPS past 5Y-38.50% ROI1.90% 52W High-20.79% Beta1.08
Dividend %- Quick Ratio7.80 Sales past 5Y5.80% Gross Margin69.30% 52W Low46.36% ATR1.62
Employees1250 Current Ratio8.40 Sales Q/Q-20.30% Oper. Margin-0.10% RSI (14)37.04 Volatility3.68% 3.33%
OptionableYes Debt/Eq0.27 EPS Q/Q-950.00% Profit Margin-1.20% Rel Volume1.70 Prev Close42.76
ShortableYes LT Debt/Eq0.27 EarningsJul 31 BMO Payout- Avg Volume743.08K Price42.97
Recom2.40 SMA20-7.59% SMA50-9.37% SMA200-3.30% Volume1,259,816 Change0.49%
31-Jul-14Reiterated Mizuho Buy $61 → $59
10-Apr-14Upgrade Mizuho Neutral → Buy $55 → $61
09-Apr-14Reiterated MKM Partners Sell $32 → $35
28-Feb-14Reiterated UBS Neutral $42 → $53
28-Feb-14Reiterated MKM Partners Sell $26 → $32
28-Feb-14Reiterated Mizuho Neutral $33 → $56
05-Dec-13Downgrade UBS Buy → Neutral $37 → $42
01-Nov-13Reiterated Mizuho Neutral $30 → $33
30-Oct-13Initiated FBR Capital Mkt Perform $31
24-May-13Reiterated UBS Buy $32 → $37
24-May-13Downgrade MKM Partners Neutral → Sell
18-Apr-13Downgrade Mizuho Buy → Neutral $30 → $26
17-Apr-13Reiterated MKM Partners Neutral $23 → $25
23-Jan-13Downgrade MKM Partners Buy → Neutral
16-Nov-12Initiated Mizuho Buy $27
25-Jan-12Upgrade MKM Partners Neutral → Buy $19 → $20
23-Aug-11Upgrade UBS Neutral → Buy $20.50 → $21
08-Jul-11Reiterated UBS Neutral $19 → $20.50
07-Jun-11Reiterated UBS Neutral $16.50 → $19
10-May-11Reiterated UBS Neutral $14.50 → $16.50
31-Jul-14 08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN -7.69%
08:19AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:35AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:07AM  Q2 2014 Alkermes plc Earnings Release - Before Market Open CCBN
07:05AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports Second Quarter 2014 Financial Results Business Wire
30-Jul-14 07:00AM  Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder Business Wire
24-Jul-14 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Business Wire
23-Jul-14 07:10AM  Is Alkermes plc Stock Undervalued? at Motley Fool
21-Jul-14 03:40PM  Alkermes' Pipeline Development Impresses, Key Updates Ahead Zacks
17-Jul-14 07:05AM  Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS at theflyonthewall.com
07:00AM  Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
09-Jul-14 07:00AM  Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Business Wire
08-Jul-14 12:47PM  Momentum names slammed as volatility comes back at CNBC
09:55AM  Why Mylan Should Buy Alkermes at Motley Fool
23-Jun-14 07:04AM  Alkermes plc (ALKS) Jumps: Stock Rises 5.7% Zacks
07:04AM  Alkermes plc (ALKS) Jumps: Stock Rises 5.7%
20-Jun-14 07:00AM  Lundbeck Delivers Some Data-Driven Upside at Seeking Alpha +5.71%
19-Jun-14 10:40AM  Alkermes' Aripiprazole Lauroxil Looks Promising Zacks
10:40AM  Alkermes' Aripiprazole Lauroxil Looks Promising
18-Jun-14 08:17AM  New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits at Forbes
08:17AM  New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits
07:03AM  Alkermes presents aripiprazole lauroxil phase 3 data theflyonthewall.com
07:03AM  Alkermes presents aripiprazole lauroxil phase 3 data
07:00AM  Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting Business Wire
07:00AM  Alkermes Presents Phase 3 Data From Successful Pivotal Study of Aripiprazole Lauroxil for Treatment of Schizophrenia at ASCP Annual Meeting
11-Jun-14 04:00PM  Alkermes Progresses with its Late Stage Candidate Zacks
04:00PM  Alkermes Progresses with its Late Stage Candidate
10-Jun-14 07:05AM  Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies at theflyonthewall.com
07:05AM  Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies
07:00AM  Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder Business Wire
07:00AM  Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder
09-Jun-14 02:27PM  What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort at The Wall Street Journal
02:27PM  What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort
06-Jun-14 03:30PM  Alkermes' Pipeline Holds Promise Zacks
03:30PM  Alkermes' Pipeline Holds Promise
05-Jun-14 12:00AM  Sanofi, Alkermes Name, Pandora: Intellectual Property at Bloomberg
12:00AM  Sanofi, Alkermes Name, Pandora: Intellectual Property
03-Jun-14 07:00AM  Alkermes to Present Data on New Medicines in Development for Schizophrenia and Depression at Upcoming American Society of Clinical Psychopharmacology Annual Meeting Business Wire
02-Jun-14 07:00AM  Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic Business Wire
31-May-14 12:47AM  [$$] Ivy Mid Cap Growth: Rethinking Risk at Barrons.com
28-May-14 04:53PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur EDGAR Online
27-May-14 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
16-May-14 08:50AM  Top Analyst Upgrades and Downgrades: J.C. Penney, Micron, Twitter, NBG, SanDisk and More at 24/7 Wall St.
05:38AM  Alkermes assumed with a Buy at Jefferies at theflyonthewall.com
14-May-14 07:16AM  Leerink to hold a bus tour at theflyonthewall.com
12-May-14 04:00PM  Alkermes Corporate Presentation to be Webcast at the UBS Global Healthcare Conference Business Wire
01-May-14 10:50AM  Wider-than-expected Loss at Alkermes, Revenues Slip Zacks
30-Apr-14 03:08PM  Alkermes' CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
08:30AM  Alkermes plc Earnings Call scheduled for 8:30 am ET today CCBN
08:25AM  Alkermes plc Discusses Q4 2014 Results (Webcast) at Seeking Alpha
07:34AM  Alkermes plc Earnings Call scheduled for 8:30 am ET today CCBN
07:13AM  Alkermes says 'on track" to submit aripiprazole lauroxil NDA in Q3 theflyonthewall.com
07:07AM  Q1 2014 Alkermes plc Earnings Release - Before Market Open CCBN
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Alkermes plc Reports First Quarter 2014 Financial Results Business Wire
23-Apr-14 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial Results Business Wire
17-Apr-14 08:31PM  Xenoport's Path Is Long, But The Potential Is There at Seeking Alpha
16-Apr-14 06:30PM  The Biggest Biotech Wins of the Week at Motley Fool +5.14%
09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks
11-Apr-14 06:41AM  Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% Zacks
10-Apr-14 03:39PM  Gilead Announces Encouraging Sovaldi Data Zacks
08:21AM  [video] Alkermes is a true drug innovator: CEO at CNBC
05:57AM  Alkermes upgraded by Mizuho Briefing.com
09-Apr-14 06:45PM  Lightning Round: Citigroup, Disney & More at CNBC +7.53%
05:30PM  Oncolytics Reports Additional Data on Reolysin Zacks
11:48AM  Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns Zacks
10:50AM  Positive Trial Data Lifts Alkermes Zacks
08-Apr-14 03:33PM  Alkermes to seek schizophrenia drug approval after trial success Reuters
03:21PM  Alkermes to seek schizophrenia drug approval after trial success Reuters
01:06PM  Why Alkermes PLC Shares Temporarily Spiked Higher at Motley Fool
12:57PM  Alkermes Scores Phase 3 Win for Long-Lasting Schizophrenia Drug at Motley Fool
12:12PM  Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3 at Investor's Business Daily
11:57AM  Alkermes to seek schizophrenia drug approval after trial success Reuters
11:51AM  [$$] Alkermes Treatment for Schizophrenia Shows Positive Results at The Wall Street Journal
11:10AM  Halozyme Falls on Phase II Study Halt Zacks
10:53AM  UPDATE 1-Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
10:40AM  Bristol-Myers Seeks FDA Approval for HCV Candidates Zacks
09:26AM  RadNet Touches New 52-Week High Zacks
09:24AM  Ahead of the Bell: Alkermes shares jump AP
09:11AM  Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment at TheStreet
08:00AM  The Boston Beer Company Earnings Call scheduled for 8:00 am ET today CCBN
08:00AM  Novartis AG Earnings Call scheduled for 8:00 am ET today CCBN
08:00AM  Alkermes Conference Call to discuss Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil scheduled for 8:00 am ET today CCBN
07:10AM  Alkermes' schizophrenia drug meets main goal of late-stage study Reuters
07:05AM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:04AM  Alkermes announces phase 3 'positive' results from aripiprazole lauroxil study at theflyonthewall.com
07:00AM  Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil for Treatment of Schizophrenia Business Wire
06:54AM  Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% Zacks
06:36AM  Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher Zacks
07-Apr-14 06:30PM  Balanced Risk-Reward for EMCOR Group Zacks
06:00PM  Halozyme Falls on Phase II Study Halt Zacks
05:25PM  Expense Woes Persist at ProAssurance Zacks
04-Apr-14 07:05AM  Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% Zacks -6.53%
03-Apr-14 05:20PM  Good News for Keryx Zacks -5.06%
05:15PM  Glaxo Stops MAGE-A3 Lung Cancer Study Zacks
03:55PM  Encouraging Results on Gilead's Sovaldi Zacks
07:21AM  What Falling Estimates & Price Mean for bluebird bio (BLUE) Zacks
06:45AM  Should You Get Rid of Synageva BioPharma (GEVA) Now? Zacks
02-Apr-14 08:02PM  Why Tesla Motors, Acceleron Pharma, and Ballard Power Systems Jumped Today at Motley Fool
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.